Therapeutic compounds
View Patent ↗The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating 5-HT2C and/or RSK disorders, including diseases and disorders mediated by GPCRs and/or RSKs.
1. A compound of formula (I):
wherein,
R 1 is independently, NH 2 , NH(R′), N(R′) 2 ;
or
wherein ring A is a 3-8 membered heterocyclic or heteroaryl, containing 0-3 additional heteroatoms selected from O, N and S; wherein ring A is optionally substituted;
each R′ is independently alkyl, alkenyl, or alkynyl, each of which may be optionally substituted;
R 2 is independently —(CH 2 )n—;
each n is independently 1 or 2;
R 3 is independently H, OH, or halo;
R 4 is independently H, OH, or halo
each R 5 is independently alkyl, aryl, halo, nitro, amino, heteroaryl, cycloalkyl, heterocyclic, or a alkoxy;
R 6 is independently H or alkyl;
R 7 independently H, or N(alkyl) 2 ; and
each R 8 is independently cycloalkyl or heterocyclic, optionally substituted with 1, 2, 3, or 4 independent R 5 ;
or salt thereof.
2. A compound of formula (I):
wherein,
R 1 is independently, NH 2 , NH(R′), N(R′) 2 ;
or
wherein ring A is a 3-8 membered heterocyclic or heteroaryl, containing 0-3 additional heteroatoms selected from O, N and S; wherein ring A is optionally substituted;
each R′ is independently alkyl, alkenyl, or alkynyl, each of which may be optionally substituted;
R 2 is independently —(CH 2 )n—;
each n is independently 1 or 2;
R 3 is independently H, OH, or halo;
R 4 is independently H, OH, or halo;
R 6 is independently H or alkyl;
R 7 independently H, or N(alkyl) 2 ; and
each R 8 is independently cycloalkyl or heterocyclic, wherein each R 8 is substituted with 2, 3 or 4 independent R 5 wherein each R 5 is independently H, alkyl, halo, aryl, nitro, amino, heteroaryl, cycloalkyl;
or salt thereof.
3. The compound of claim 1 , wherein R 1 and R 8 are trans-oriented to one another.
4. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
5. A method of making a composition of claim 4 comprising combining a compound of claim 1 and a pharmaceutically acceptable carrier.
6. The compound of claim 1 , wherein the compound is 4-cyclohexyl-N, N-dimethyl-1,2,3,4-tetrahydronaphthalen-2-amine.
7. The compound of claim 1 , wherein the compound is (2S,4R)-4-cyclohexyl-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-2-amine.
8. The compound of claim 1 , wherein R 8 is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.